{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:22:26Z","timestamp":1769829746942,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","award":["PE00000006"],"award-info":[{"award-number":["PE00000006"]}],"id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.msard.2023.105135","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:55:49Z","timestamp":1699721749000},"page":"105135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-8477","authenticated-orcid":false,"given":"Daniele","family":"Caliendo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmela","family":"Grassia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Petracca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2613-3090","authenticated-orcid":false,"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105135_bib0001","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.3390\/cells11132058","article-title":"Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives","volume":"11","author":"Bravo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.msard.2023.105135_bib0002","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.105135_bib0003","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s40265-017-0814-1","article-title":"Benefit\u2013Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis","volume":"77","author":"Comi","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.msard.2023.105135_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101938","article-title":"Severe fingolimod rebound syndrome after switching to cladribine treatment","volume":"40","author":"Coss-Rovirosa","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105135_bib0005","unstructured":"EMA, 2023. Gilenya\u00a0: EPAR - Product Information [WWW Document]. First published: 30\/03\/2011 Last updated: 15\/09\/2023 URL https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf."},{"key":"10.1016\/j.msard.2023.105135_bib0006","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav. Res. Methods"},{"key":"10.1016\/j.msard.2023.105135_bib0007","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.msard.2017.11.018","article-title":"Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod","volume":"19","author":"Fragoso","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105135_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/neurolint12030016","article-title":"Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects","volume":"12","author":"Lassiter","year":"2020","journal-title":"Neurol. Int."},{"key":"10.1016\/j.msard.2023.105135_bib0009","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2023.105135_bib0010","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1212\/NXI.0000000000000874","article-title":"Lymphocyte recovery after fingolimod discontinuation in patients with MS","volume":"7","author":"Nagy","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.msard.2023.105135_bib0011","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1212\/NXI.0000000000000874","article-title":"Lymphocyte recovery after fingolimod discontinuation in patients with MS","volume":"7","author":"Nagy","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflam."},{"key":"10.1016\/j.msard.2023.105135_bib0012","article-title":"Risk factors for fingolimod-induced lymphopenia in multiple sclerosis","volume":"4","author":"Ohtani","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2023.105135_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2023.105135_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/cer-2019-0169","article-title":"Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis","volume":"9","author":"Swallow","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.msard.2023.105135_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104551","article-title":"Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison","volume":"71","author":"Swallow","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2023.105135_bib0016","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.msard.2023.105135_bib0017","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2015.05.012","article-title":"Safety and efficacy of reduced fingolimod dosage treatment","volume":"285","author":"Yamout","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2023.105135_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1352458517694089","article-title":"Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study","volume":"24","author":"Zecca","year":"2018","journal-title":"Mult. Scler. J."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823006363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:02:20Z","timestamp":1719968540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823006363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":18,"alternative-id":["S2211034823006363"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105135","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105135"}}